IOL Chemicals and Pharmaceuticals has kicked off FY27 on a strong note, posting a sharp rise in revenue and an almost 90% jump in standalone net profit for the quarter ended June 30, 2026.

 

Revenue from operations surged 37.1% year-on-year (YoY) to Rs. 756.3 crore in Q1 FY27, compared with Rs. 551.7 crore in the year-ago quarter. On a sequential basis, revenue climbed 22.1%, from Rs. 619.5 crore in Q4 FY26.

 

The company’s operating performance strengthened significantly, with EBITDA rising 60.7% YoY to Rs. 111.7 crore, compared with Rs. 69.5 crore a year earlier. EBITDA was also up 18.5% quarter-on-quarter, from Rs. 94.3 crore in Q4 FY26.

 

The EBITDA margin expanded to 14.6%, up 220 basis points from 12.4% in Q1 FY26, although it was slightly lower than the 15.2% recorded in the preceding quarter.

 

The bottom line delivered an even stronger performance. Profit after tax (PAT) jumped 89.9% YoY to Rs. 64.5 crore, nearly doubling from Rs. 34 crore in Q1 FY26. PAT also rose 21.2% sequentially from Rs. 53.2 crore in Q4 FY26.

 

PAT margin widened to 8.4%, compared with 6.1% a year earlier, marking an improvement of 230 basis points. The margin remained broadly stable sequentially against 8.6% in Q4 FY26.

 

For context, IOL Chemicals reported Rs. 2,319.1 crore in revenue, Rs. 290.4 crore in EBITDA and Rs. 137.7 crore in PAT for full-year FY26.

 

Commenting on the performance, Vikas Gupta, Joint Managing Director said, "We have commenced FY27 with a record quarterly performance, delivering our highest-ever revenue. This performance is particularly encouraging given the backdrop of geopolitical uncertainties, supply chain disruptions, and inflationary pressures across select raw materials. Healthy growth and year-on-year margin expansion were supported by improved capacity utilisation, favourable product mix and operational efficiencies.

 

"Our Pharmaceuticals business remained a key growth driver, with revenue increasing 43% YoY and EBIT growing 72% YoY. Non-Ibuprofen products contributed 43% of Pharma revenue in Q1 FY27, up from 36% a year ago, led by healthy demand across Paracetamol, Pantoprazole, Metformin, Fenofibrate and other APIs. Paracetamol capacity utilisation also improved to 65% from 60% in the previous quarter."

 

He added: "The Chemicals business delivered 29% YoY revenue growth and 193% YoY EBIT growth, supported by improved operational efficiencies, disciplined and efficient raw-material procurement, better realisations and higher exports.

 

"Our overall export performance continued to strengthen, with exports contributing 28.5% of revenue compared with 24.4% in Q1 FY26, reflecting growing traction across international markets. We are also pleased to share that our Clopidogrel API product has received NMPA approval in China, in addition to our valid CEP, further expanding our access to the Chinese pharmaceutical market.

 

"Going forward, we remain focused on scaling our portfolio, improving product mix, enhancing capacity utilization, and expanding our presence across value-added APIs and specialty chemicals. We remain confident of building on this momentum and delivering sustainable long-term growth."